Table 2.

CD19 B cell suppression and clinical outcome (at the time of first dose of rituximab infusion) of the study participants

TimeFrequently Relapsing Nephrotic Syndrome/Steroid-Dependent Nephrotic Syndrome (n=30)Membranous Nephropathy (n=5)Transplant Recipients (n=7)
Day 30
 Absolute CD19 B cell count, mean (no/µl)1.5±2.45.0±3.70
 CD19 B cell percentage, mean0.3±0.30.2±0.20
 CD19 B cell suppression <1%, number (%)28 (93.3)5 (100)7 (100)
 Remission, number (%)29 (96.7)0NA
 Acute rejection episodes, number (%)NANA2 (14.2)
Day 90
 Absolute CD19 B cell count, mean (no/µl)13.2±17.348.4±8.90
 CD19 B cell percentage, mean2.0±1.91.5±0.50
 CD19 B cell suppression <1%, number (%)10 (33.3)1 (20)7 (100)
 Remission, number (%)29 (96.7)4 (80)aNA
 Acute rejection episodes, number (%)NANA2 (28.5)
Day 180
 Absolute CD19 B cell count, mean (no/µl)155.0±162.879.0±12.30
 CD19 B cell percentage, mean6.2±4.84.1±0.30
 CD19 B cell suppression <1%, number (%)007 (100)
 Remission, number (%)23 (76.6)4 (80)bNA
 Acute rejection episodes, number (%)NANA2 (28.5)
1 yr
 Remission, number (%)21 (70)3 (60)cNA
 Acute rejection episodes, number (%)NANA2 (28.5)
  • NA, not applicable.

  • a Partial remission in three, complete remission in one.

  • b Partial remission in two, complete remission in two.

  • c Partial remission in one, complete remission in two.